Valid today –Bright Minds Biological Sciences The shares will begin trading on the NASDAQ stock exchange under the ticker symbol “DRUG”. Bright Minds is already listed on the Canadian Stock Exchange (CSE: DRUG) under the same symbol. Nasdaq Stock Market LLC has agreed to list the company’s common stock on the Nasdaq Stock Exchange.
The team of drug designers at Bright Minds has developed narcotic drugs to make them safer and more accessible to a greater number of patients, often people who do not have options when dealing with treatment-resistant cases. The company has several patented drugs in the pipeline — primarily 5-HT2C and 5-HT2C + 5HT2A — that are currently in the late preclinical stage.
A particularly intractable epilepsy common in children, Dravet’s syndrome difficult to manage using traditional medicines. This is why a number of patients resort to the use of cannabis, which is itself a mild anesthetic, to combat it. For example, Charlotte’s web shares the name of the late Charlotte Fiji for which the breed is named. Now, scientists are exploring psychedelic drugs to fight the condition as well, which so far show remarkable abilities.
The company’s main new compound – BMB-101 – has shown efficacy in in the laboratory And in vivo Preclinical studies of pediatric epilepsy reduced seizure duration by 74 percent. The company plans to advance clinical trials with the compound in early 2022.
The leadership of Bright Mind Biosciences is very excited about The drug revolution This is reinventing therapy as we know it. Renewed interest in the medical benefits of drugs such as psilocybin, ketamine, MDMA, etc. is everywhere.
We make drugs [of] The 60’s are great again! And to be honest, better than they were in those days thanks to modern scientific knowledge and helping a lot of patients along the way,” said Ian MacDonald, CEO of Bright Mind Biosciences. High Times.
Bright Minds has a line of serotonin agonists designed to target “neural circuit abnormalities” responsible for hard-to-treat disorders such as intractable epilepsy, treatment-resistant depression, post-traumatic stress disorder, and pain. The company makes compounds with the goal of reducing the side effects of first-generation narcotic drugs such as psilocybin.
MacDonald also acknowledged the distressing situation that people with Dravet syndrome face in a press release. “Our Nasdaq listing represents an important milestone for Bright Minds as we continue to develop our innovative drug candidates in pursuit of an improved generation of targeted serotonin-based therapies,” MacDonald said. “With preclinical data encouraged across many indications, we are progressing toward first human trials with our lead drug candidate, BMB-101, for the treatment of Dravet syndrome, a devastating congenital and genetic disease affecting the nervous system. We expect to begin trials in the first half of the year. 2022.”
Last August, the company announced that the BMB-101 Shown efficacy in rodent models of Dravet syndrome. Moreover, the effect of BMB compounds was consistent and comparable with other pharmaceutical antiepileptics such as fenfluramine.
BMB-101 is a selective and biased 5-HT2C agonist, which shows convincing promise in medical treatments for Dravet syndrome and/or other diseases.
BMB-101 works differently from cannabinoids, like THC, and there are no cannabinoids or other terpenoids found in the substance of the cannabis plant. Known direct effects on the receptors drug-related in similar chapters.
The Nasdaq listing puts Bright Minds in a much more competitive position in an already competitive psychedelic scene.
“Bright Minds is also committed to delivering significant returns to our shareholders,” McDonald’s continued. “Trading in the world’s most liquid market in which all investors can participate helps us continue to achieve this goal. We look forward to continuing to work closely with all of our key components – the scientific, medical and capital markets – to enhance our excellent competitive position.”